440 related articles for article (PubMed ID: 7514319)
41. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.
Langedijk JP; Zwart G; Goudsmit J; Meloen RH
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1153-62. PubMed ID: 8573370
[TBL] [Abstract][Full Text] [Related]
42. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
Neurath AR; Strick N; Lee ES
J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
[TBL] [Abstract][Full Text] [Related]
43. IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection.
Chiodi F; Mathiesen T; Albert J; Parks E; Norrby E; Wahren B
J Immunol; 1989 Jun; 142(11):3809-14. PubMed ID: 2497181
[TBL] [Abstract][Full Text] [Related]
44. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products.
Pollock BJ; McKenzie AS; Kemp BE; McPhee DA; D'Apice AJ
Clin Exp Immunol; 1989 Dec; 78(3):323-8. PubMed ID: 2482145
[TBL] [Abstract][Full Text] [Related]
45. Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA.
Tiwari RP; Jain A; Khan Z; Kumar P; Bhrigu V; Bisen PS
J Immunol Methods; 2013 Jan; 387(1-2):157-66. PubMed ID: 23098841
[TBL] [Abstract][Full Text] [Related]
46. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.
Barin F; Meyer L; Lancar R; Deveau C; Gharib M; Laporte A; Desenclos JC; Costagliola D
J Clin Microbiol; 2005 Sep; 43(9):4441-7. PubMed ID: 16145089
[TBL] [Abstract][Full Text] [Related]
47. Design and synthesis of a self-assembling peptide derived from the envelope proteins of HIV type 1. An approach to heterovalent immunogens.
Tripathy SP; Kumar A; Manivel V; Panda SK; Rao KV
J Immunol; 1992 Jun; 148(12):4012-20. PubMed ID: 1534827
[TBL] [Abstract][Full Text] [Related]
48. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
49. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.
Loomis-Price LD; Cox JH; Mascola JR; VanCott TC; Michael NL; Fouts TR; Redfield RR; Robb ML; Wahren B; Sheppard HW; Birx DL
J Infect Dis; 1998 Nov; 178(5):1306-16. PubMed ID: 9780250
[TBL] [Abstract][Full Text] [Related]
50. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.
Zwart G; Wolfs TF; Valk M; Van der Hoek L; Kuiken CL; Goudsmit J
AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1897-908. PubMed ID: 1489578
[TBL] [Abstract][Full Text] [Related]
51. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
[TBL] [Abstract][Full Text] [Related]
52. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
53. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
54. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
Goudsmit J; Bakker M; Smit L; Meloen RH
J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
[TBL] [Abstract][Full Text] [Related]
55. Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope.
Back NK; Haigwood NL; de Wolf F; de Jongh BM; Goudsmit J
Intervirology; 1991; 32(3):160-72. PubMed ID: 2040587
[TBL] [Abstract][Full Text] [Related]
56. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection.
Koup RA; Pikora CA; Mazzara G; Panicali D; Sullivan JL
Viral Immunol; 1991; 4(4):215-23. PubMed ID: 1726398
[TBL] [Abstract][Full Text] [Related]
57. Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals.
Enshell-Seijffers D; Smelyanski L; Vardinon N; Yust I; Gershoni JM
FASEB J; 2001 Oct; 15(12):2112-20. PubMed ID: 11641237
[TBL] [Abstract][Full Text] [Related]
58. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop).
Lucey DR; VanCott TC; Loomis LD; Bethke FR; Hendrix CW; Melcher GP; Redfield RR; Birx DL
J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):994-1001. PubMed ID: 7688046
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
Ampol S; Pattanapanyasat K; Sutthent R; Permpikul P; Kantakamalakul W
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1250-8. PubMed ID: 22288892
[TBL] [Abstract][Full Text] [Related]
60. Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41.
Matsuda S; Noda M
Microbiol Immunol; 2000; 44(11):923-9. PubMed ID: 11145273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
